Pfizer's Q3 Success and Biopharma Updates: A Daily Dose of Pharma and Biotech News

Pharma and BioTech Daily

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world. Pfizer exceeded Wall Street's expectations in the third quarter, reporting higher revenue and adjusted profit amid pressure from activist investor Starboard Value. CEO Albert Bourla received a much-needed victory as the company performed well despite the challenges. In other news, Novartis also beat analyst expectations in Q3, driven by strong sales of Cosentyx. Wuxi Apptec, a Chinese contract manufacturer, continues to attract new clients despite potential threats from the BioSecure Act. The upcoming presidential election could impact the biopharma industry differently under Harris or Trump, with some analysts suggesting Trump may be more positive for the industry overall. Pfizer's success in Q3 and other developments in the biopharma industry, including new partnerships and drug approvals, are also highlighted.